RTs Three Key Takeaways: GLP-1 Agonists Improve Asthma Control GLP-1 agonists like Ozempic and Mounjaro were linked to reduced asthma symptoms and medication use in obese patients, beyond their role in weight loss
Brand-name GLP-1s (like Wegovy, Ozempic, Mounjaro): FDA-approved, backed by clinical trials, usually insurance-driven, but very expensive if not covered
Novos general counsel John Kuckelman told CNBC it may have been accurate for Lilly to boast about Zepbounds greater efficacy before the 7.2 milligram dose of Wegovy became available, but it is no longer accurate to say that. Novos suit says Lilly acknowledges a higher dose of Wegovy in a brief footnote in the television ad, but it says the footnote is ambiguous, confusing, virtually illegible, and wholly inadequate. key background Novo Nordisk and Eli Lilly, chief rivals in the booming GLP-1 industry, have struggled for dominance over the obesity medication market, with Novos market share slipping from an early lead
Use a small box or container as a buffer